A. L. Zubarev

A. L. Zubarev

Auto-generated profile, based on publicly available information

A. L. Zubarev

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
VIV. E. Ivanov
V. E. Ivanov
AКArray А. Курильчик
Array А. Курильчик
YRYu. A. Ragulin
Yu. A. Ragulin
AЖArray А. Жеравин
Array А. Жеравин
ASA. L. Starodubtsev
A. L. Starodubtsev
AЗArray Л. Зубарев
Array Л. Зубарев
Введение. Остеогенная саркома относится к высокозлокачественным новообразованиям скелета и составляет до 6 % от всех костных опухолей. В литературе описаны единичные случаи первичной остеосаркомы грудины. Особый интерес представляет возможность выполнения расширенных радикальных оперативных вмешательств на грудной стенке с одномоментной комбинированной реконструкцией реберного каркаса имплантатами из биологически совместимых материалов. Материал и методы. Представлен случай редкой локализации остеосаркомы в области грудины у 49-летней пациентки. Больной было проведено комбинированное лечение, включающее курсы химиотерапии, лучевую терапию и хирургические вмешательства на первичном очаге и легких. Для замещения дефекта каркаса грудной стенки использовали имплантаты из никелида титана. Результаты. Активная лечебная тактика, включающая химиотерапию и хирургические этапы, позволила достичь оптимального качества жизни на протяжении 21 мес у пациентки с крайне неблагоприятным прогнозом. Заключение. Представленный способ реконструкции каркаса грудной стенки с использованием биосовместимых материалов из никелид-титана является эффективным и безопасным для использования у пациентовсо злокачественными новообразованиями грудной стенки.

20 August 2021 in Grekov's Bulletin of Surgery
Verified
Journal Article
Open access
PDF file
AKA. A. Kurilchik
A. A. Kurilchik
VUV. S. Usachev
V. S. Usachev
VIV. E. Ivanov
V. E. Ivanov
ASA. L. Starodubtsev
A. L. Starodubtsev
AZA. L. Zubarev
A. L. Zubarev
INTRODUCTION. Chest wall tumors represent a variety of morphological forms and variants of lesions. According to different authors, primary malignant tumors of the chest wall account for 0.2–2 % of all malignant neoplasms. Of them, soft tissue sarcomas constitute about 45 %. Metastatic tumors of the chest wall occur much more frequently and most commonly develop from malignant tumors of the mammary, prostate and thyroid glands, lungs, kidneys and ovaries.MATERIALS AND METHODS. The standard of the treatment of primary and metastatic tumors of the chest wall is combination or comprehensive therapy. In some cases, preoperative care allows to create a more favorable environment for performing surgical treatment being considered the best option for chest wall tumors. The choice of a technique for the replacement of the post-resection chest wall defect is of special importance to preserve the physiological chest volume, to restore chest rigidity, to prevent paradoxical respiration and to seal the pleural cavity.RESULTS. There are different surgical techniques for skeleton reconstruction. A wide range of materials used for a skeleton reconstruction include bone tissues obtained from patient’s own body (bone autoplasty, autografts), polymeric mesh (polypropylene, polytetrafluoroethylene (Gore-Tex), bone cement (polymethyl methacrylate), stainless steel and titanium constructions as well as titanium bars and rib clips (STRATOS). In spite of a large number of techniques for sternal reconstruction described in the literature, searching for new materials and ways of their usage appears relevant.CONCLUSION. Our clinical case studies demonstrate that modern reconstructive techniques combined with careful surgical planning allow to perform radical surgery with a successful outcome preventing serious postoperative complications.

22 April 2023 in Bone and soft tissue sarcomas, tumors of the skin
Verified
Journal Article
Open access
PDF file
OAO. E. Abramova
O. E. Abramova
DKD. V. Kudryavtsev
D. V. Kudryavtsev
AKA. A. Kurilchik
A. A. Kurilchik
SIS. A. Ivanov
S. A. Ivanov
Regional recurrences are one of the most common first manifestations of progression of clinically localized cutaneous melanoma. They are caused by subclinical metastases in the lymph nodes. Biopsy of the sentinel lymph nodes is the most effective method of detection of hidden regional metastases. It allows to appropriately increase the volume of surgical treatment prior to dissection of the affected lymph collector and perform adjuvant therapy with the most effective drugs. This, in its turn, allows for significant improvement of regional and systemic control of the disease and long-term treatment outcomes.Data obtained in several randomized trials on the effectiveness of lymph node dissection in patients with sentinel lymph node metastasis showed that this procedure significantly improves regional control of the disease but does not affect long-term treatment outcomes. Additionally, some studies showed that assignment of responsibility for regional control to adjuvant therapy does not meet the expectations. Therefore, the most effective method of regional control of cutaneous melanoma is surgery. All of these studies show that it is necessary to develop criteria for identification of patients with high risk of metastases in the non-sentinel lymph nodes who require lymph node dissection for regional disease control and creation of the best conditions for adjuvant systemic therapy. This requires identification of predictors of multiple involvement of regional lymph nodes justifying indications for radical lymph node dissection. Studies in this area are being performed but their results are ambiguous and sometimes contradictory.Aim. To evaluate the effectiveness of lymph node biopsy and radical lymph node dissection in patients with cutaneous melanoma and subclinical involvement of the sentinel lymph node.

12 October 2022 in Bone and soft tissue sarcomas, tumors of the skin
Verified
Journal Article
Open access
PDF file
AKA. A. Kurilchik
A. A. Kurilchik
VIV. E. Ivanov
V. E. Ivanov
ASA. L. Starodubtsev
A. L. Starodubtsev
AZA. L. Zubarev
A. L. Zubarev
MAM. D. Aliev
M. D. Aliev
Introduction. Routine endoprosthesis production does not have ready solutions for such rare locations as forearm bones, scapula, and breastbone. In the last decade, 3D printing of personalized implants has been actively developing. Its benefits are accurate anatomical compliance with the resected segment, quick manufacturing time, and low cost. Oncoortopedics finds use of more additional technologies.Aim. To show through clinical observations the advantages of qualitatively new biologically and mechanically compatible implants used to replace bone defects in anatomically complex locations and to promote the use of such endoprosthesis in clinical practice.Materials and methods. Organ-saving treatment using personalized implants manufactured using 3D printing technology was performed in 7 patients with bone tumors: 3 with primary bone tumors (sarcomas) and 4 with metastases. Tumor lesions were localized in the humerus in 2 cases, in the scapula in 2 cases, in the breastbone in 2 cases, and in the distal part of the radius in 1 case. The implants were designed based in the spiral computed tomography data. For implant manufacturing, direct metal laser sintering (DMLS) was used. Titanium alloy Ti6Al4V certified for production of medical implants was used as the material. Design and manufacturing took 3 weeks.Results. Morphological examination showed negative tumor resection margin in all patients. All 7 patients are alive. No intraoperative complications were reported. Follow up varied between 1 and 8 months. During follow up, disease progression was not observed. Mean functional score per the Musculoskeletal Tumour Society score (MSTS) was 80 % (between 72 and 94 %).Conclusion. Development of qualitatively new Russian oncological implants using 3D-printing technology is one of the most important areas in bone pathology.

20 August 2021 in Grekov's Bulletin of Surgery
Verified
Journal Article
Open access
PDF file
AKA. A. Kurilchik
A. A. Kurilchik
VIV. E. Ivanov
V. E. Ivanov
ASA. L. Starodubtsev
A. L. Starodubtsev
AZA. L. Zubarev
A. L. Zubarev
This study was aimed to analyze the most common diagnostic and therapeutic errors in orthopaedic oncological diseases. Bone tumors usually do not have characteristic symptoms, especially in the early stages of disease development. Therefore, they can often mimic benign tumors and non-tumor diseases. Careful history taking, detailed clinical and X-ray examinations in a timely manner are essential diagnostic tools for patients with bone sarcomas. Moreover, a correct analysis of clinical and radiological findings with regard to the dynamic relationship between them can help make more accurate diagnosis at the first doctor’s visit. Subsequent X-ray examinations performed in oncological centers using special methods such as spiral CТ, MRI, PET/CT with mandatory morphological verification of the diagnosis enable us to make a more precise diagnosis and to provide an objective assessment of pathological processes. The most common diagnostic and therapeutic errors that occur in orthopaedic oncological diseases were analyzed. In 35 % of cases, diagnostic or tactical errors were made by general practitioners. In 15 % of cases, the errors were associated with a latent course of disease and 12 % of cases were wrongly diagnosed as a benign neoplasm.

12 September 2024 in Bone and soft tissue sarcomas, tumors of the skin
Verified
Journal Article
Open access
PDF file
AZA. L. Zubarev
A. L. Zubarev
AKA. A. Kurilchik
A. A. Kurilchik
VIV. E. Ivanov
V. E. Ivanov
ASA. L. Starodubtsev
A. L. Starodubtsev
MKM. K. Khanina
M. K. Khanina
Soft tissue sarcomas are a rare and heterogeneous group of solid tumors originating from the mesenchyme and accounting for only 1 % of all malignant neoplasms in adults. The modern clinical and morphological World Health Organization of soft tissue sarcomas classification includes more than 100 forms of these tumors. Neurofibromatosis is a group of hereditary, autosomal dominant diseases characterized by the development of multiple tumor formations, often benign. Currently, there are 3 types: neutrophibromatosis type I, neurofibromatosis type II and schwannomatosis. The estimated risk of developing sarcoma in patients with neurofibromatosis type 1 at age 30 years is 25.1 %, and by age 50 years it is 38.8 %. Treatment of soft tissue sarcomas associated with neurofibromatosis fully complies with the standard recommendations of National Comprehensive Cancer Network, NCCN (NCCN), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO) and RUSSCO and does not have its own peculiarities. Over the past 15 years, at the A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, more than 190 patients with locally advanced, high-grade soft tissue sarcomas have been treated, including five patients with sarcomas associated with neurofibromatosis. The article presents clinical cases of treatment of soft tissue sarcomas associated with neurofibromatosis.